Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic
Demyelinating disorders of the central white matter are among the most prevalent and disabling conditions in neurology. Since myelin-producing oligodendrocytes comprise the principal cell type deficient or lost in these conditions, their replacement by new cells generated from transplanted bipotenti...
Gespeichert in:
| Veröffentlicht in: | Seminars in cell & developmental biology 2021-08, Vol.116, p.62-70 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 70 |
|---|---|
| container_issue | |
| container_start_page | 62 |
| container_title | Seminars in cell & developmental biology |
| container_volume | 116 |
| creator | Goldman, Steven A. Mariani, John N. Madsen, Pernille M. |
| description | Demyelinating disorders of the central white matter are among the most prevalent and disabling conditions in neurology. Since myelin-producing oligodendrocytes comprise the principal cell type deficient or lost in these conditions, their replacement by new cells generated from transplanted bipotential oligodendrocyte-astrocyte progenitor cells has emerged as a therapeutic strategy for a variety of primary dysmyelinating diseases. In this review, we summarize the research and clinical considerations supporting current efforts to bring this treatment approach to patients. |
| doi_str_mv | 10.1016/j.semcdb.2020.12.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8254822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1084952120301981</els_id><sourcerecordid>2476558495</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-62e7ea29f5748a4fe0ae2c24cc2b99eb56307c3aeb91882644a4d8a50dbafa803</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBAISuEPEMqRS4rtOK7DAQkhKEiV4AASN2vjbIqrJC52itS_x6XldeHklXdmdneGkBNGR4wyeT4fBWxNVY445fGLjygVO2TAaCHTTGZid10rkRY5ZwfkMIQ5jYiCy31ykGWCCSrpgLxMGgtNsvBuhp3tnU8MNk1aQsAq8bgA6xNXJ_0rJtUqtCtsbAd97JUebHeRPEaixxCs65LefeJMhFhzRPZqaAIeb98heb69ebq-S6cPk_vrq2lqhMz6VHIcI_CizsdCgaiRAnLDhTG8LAosc5nRsckAy4IpxaUQICoFOa1KqEHRbEguN7qLZdliZbDrPTR64W0LfqUdWP2309lXPXPvWvFcKM6jwNlWwLu3JYZetzasTYAO3TJoLsYyz5Uo8ggVG6jxLgSP9fcYRvU6FD3Xm1D0OhTNuI6WR9rp7xW_SV8p_NyA0ah3i14HY7EzWFmPpteVs_9P-ACxFKGv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2476558495</pqid></control><display><type>article</type><title>Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Goldman, Steven A. ; Mariani, John N. ; Madsen, Pernille M.</creator><creatorcontrib>Goldman, Steven A. ; Mariani, John N. ; Madsen, Pernille M.</creatorcontrib><description>Demyelinating disorders of the central white matter are among the most prevalent and disabling conditions in neurology. Since myelin-producing oligodendrocytes comprise the principal cell type deficient or lost in these conditions, their replacement by new cells generated from transplanted bipotential oligodendrocyte-astrocyte progenitor cells has emerged as a therapeutic strategy for a variety of primary dysmyelinating diseases. In this review, we summarize the research and clinical considerations supporting current efforts to bring this treatment approach to patients.</description><identifier>ISSN: 1084-9521</identifier><identifier>EISSN: 1096-3634</identifier><identifier>DOI: 10.1016/j.semcdb.2020.12.004</identifier><identifier>PMID: 33414060</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Cell Differentiation ; Cell transplant ; Cuprizone ; Demyelinating disease ; Demyelinating Diseases - physiopathology ; Glial progenitor ; Humans ; Leukodystrophy ; Multiple sclerosis ; Neural stem cell ; Neuroglia - metabolism ; Oligodendrocytic progenitor ; Stem Cells - metabolism</subject><ispartof>Seminars in cell & developmental biology, 2021-08, Vol.116, p.62-70</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-62e7ea29f5748a4fe0ae2c24cc2b99eb56307c3aeb91882644a4d8a50dbafa803</citedby><cites>FETCH-LOGICAL-c463t-62e7ea29f5748a4fe0ae2c24cc2b99eb56307c3aeb91882644a4d8a50dbafa803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.semcdb.2020.12.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33414060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goldman, Steven A.</creatorcontrib><creatorcontrib>Mariani, John N.</creatorcontrib><creatorcontrib>Madsen, Pernille M.</creatorcontrib><title>Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic</title><title>Seminars in cell & developmental biology</title><addtitle>Semin Cell Dev Biol</addtitle><description>Demyelinating disorders of the central white matter are among the most prevalent and disabling conditions in neurology. Since myelin-producing oligodendrocytes comprise the principal cell type deficient or lost in these conditions, their replacement by new cells generated from transplanted bipotential oligodendrocyte-astrocyte progenitor cells has emerged as a therapeutic strategy for a variety of primary dysmyelinating diseases. In this review, we summarize the research and clinical considerations supporting current efforts to bring this treatment approach to patients.</description><subject>Animals</subject><subject>Cell Differentiation</subject><subject>Cell transplant</subject><subject>Cuprizone</subject><subject>Demyelinating disease</subject><subject>Demyelinating Diseases - physiopathology</subject><subject>Glial progenitor</subject><subject>Humans</subject><subject>Leukodystrophy</subject><subject>Multiple sclerosis</subject><subject>Neural stem cell</subject><subject>Neuroglia - metabolism</subject><subject>Oligodendrocytic progenitor</subject><subject>Stem Cells - metabolism</subject><issn>1084-9521</issn><issn>1096-3634</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctOwzAQtBAISuEPEMqRS4rtOK7DAQkhKEiV4AASN2vjbIqrJC52itS_x6XldeHklXdmdneGkBNGR4wyeT4fBWxNVY445fGLjygVO2TAaCHTTGZid10rkRY5ZwfkMIQ5jYiCy31ykGWCCSrpgLxMGgtNsvBuhp3tnU8MNk1aQsAq8bgA6xNXJ_0rJtUqtCtsbAd97JUebHeRPEaixxCs65LefeJMhFhzRPZqaAIeb98heb69ebq-S6cPk_vrq2lqhMz6VHIcI_CizsdCgaiRAnLDhTG8LAosc5nRsckAy4IpxaUQICoFOa1KqEHRbEguN7qLZdliZbDrPTR64W0LfqUdWP2309lXPXPvWvFcKM6jwNlWwLu3JYZetzasTYAO3TJoLsYyz5Uo8ggVG6jxLgSP9fcYRvU6FD3Xm1D0OhTNuI6WR9rp7xW_SV8p_NyA0ah3i14HY7EzWFmPpteVs_9P-ACxFKGv</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Goldman, Steven A.</creator><creator>Mariani, John N.</creator><creator>Madsen, Pernille M.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210801</creationdate><title>Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic</title><author>Goldman, Steven A. ; Mariani, John N. ; Madsen, Pernille M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-62e7ea29f5748a4fe0ae2c24cc2b99eb56307c3aeb91882644a4d8a50dbafa803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Animals</topic><topic>Cell Differentiation</topic><topic>Cell transplant</topic><topic>Cuprizone</topic><topic>Demyelinating disease</topic><topic>Demyelinating Diseases - physiopathology</topic><topic>Glial progenitor</topic><topic>Humans</topic><topic>Leukodystrophy</topic><topic>Multiple sclerosis</topic><topic>Neural stem cell</topic><topic>Neuroglia - metabolism</topic><topic>Oligodendrocytic progenitor</topic><topic>Stem Cells - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goldman, Steven A.</creatorcontrib><creatorcontrib>Mariani, John N.</creatorcontrib><creatorcontrib>Madsen, Pernille M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in cell & developmental biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goldman, Steven A.</au><au>Mariani, John N.</au><au>Madsen, Pernille M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic</atitle><jtitle>Seminars in cell & developmental biology</jtitle><addtitle>Semin Cell Dev Biol</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>116</volume><spage>62</spage><epage>70</epage><pages>62-70</pages><issn>1084-9521</issn><eissn>1096-3634</eissn><abstract>Demyelinating disorders of the central white matter are among the most prevalent and disabling conditions in neurology. Since myelin-producing oligodendrocytes comprise the principal cell type deficient or lost in these conditions, their replacement by new cells generated from transplanted bipotential oligodendrocyte-astrocyte progenitor cells has emerged as a therapeutic strategy for a variety of primary dysmyelinating diseases. In this review, we summarize the research and clinical considerations supporting current efforts to bring this treatment approach to patients.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>33414060</pmid><doi>10.1016/j.semcdb.2020.12.004</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1084-9521 |
| ispartof | Seminars in cell & developmental biology, 2021-08, Vol.116, p.62-70 |
| issn | 1084-9521 1096-3634 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8254822 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Cell Differentiation Cell transplant Cuprizone Demyelinating disease Demyelinating Diseases - physiopathology Glial progenitor Humans Leukodystrophy Multiple sclerosis Neural stem cell Neuroglia - metabolism Oligodendrocytic progenitor Stem Cells - metabolism |
| title | Glial progenitor cell-based repair of the dysmyelinated brain: Progression to the clinic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A18%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glial%20progenitor%20cell-based%20repair%20of%20the%20dysmyelinated%20brain:%20Progression%20to%20the%20clinic&rft.jtitle=Seminars%20in%20cell%20&%20developmental%20biology&rft.au=Goldman,%20Steven%20A.&rft.date=2021-08-01&rft.volume=116&rft.spage=62&rft.epage=70&rft.pages=62-70&rft.issn=1084-9521&rft.eissn=1096-3634&rft_id=info:doi/10.1016/j.semcdb.2020.12.004&rft_dat=%3Cproquest_pubme%3E2476558495%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2476558495&rft_id=info:pmid/33414060&rft_els_id=S1084952120301981&rfr_iscdi=true |